logo IMeN

Tratamento cirúrgico da obesidade



( adaptado do capítulo – Obesidade – IDPC)

Dra. Cristiane Moulin
Endocrinologista - IMeN

Obesos grau III têm pior resposta ao tratamento clínico, com manutenção do peso perdido somente em 5-10% dos casos (55). A cirurgia bariátrica é atualmente a única terapia efetiva para obesidade grave. Não é considerada como cura, porém há melhora importante das comorbidades e promove perda de peso durável (56). É apenas uma parte de uma estratégia multidisciplinar para tratar obesidade grave. As taxas de morbi-mortalidade são pequenas, porém cada caso deve ser considerado individualmente, avaliando-se os riscos e benefícios. Os pacientes perdem em média: 40-75 % do excesso de peso ou 30-40% do peso inicial, dependendo da técnica específica (56). O sucesso da cirurgia é definido pela manutenção da perda de 50% do excesso de peso por 5 anos.
A cirurgia bariátrica está indicada em pacientes com IMC ³ 40kg/m2  ou ³ 35kg/m2 com comorbidades ou 200% acima do peso ideal (depende da população estudada: diferenças culturais), não respondedores ao tratamento clínico, conscientes dos riscos,desconfortos e necessidade de acompanhamento (57), em locais com equipe especializada disponível.


Referências para aprofundar o conhecimento

1.    Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among USA adults, 1999-2000. JAMA 2002; 288: 1723-7.
2.    Monteiro CA, Conde WL. A tendência secular da obesidade segundo estratos sociais: Nordeste e Sudeste do Brasil, 1975-1989-1997. Arq Bras Endocrinol Metab 1999; 43: 186-94.
3.    Sichieri R, Coitinho DC, Leão MM, Recine E, Everhart JE. High temporal, geographic, and income variation in body mass index among adults in Brazil. Am J Public Health 1994; 84: 793-8.
4.    Pesquisa de Orçamentos Familiares 2002-2003: análise da disponibilidade domiciliar de alimentos e do estado nutricional no Brasil. IBGE (Instituto Brasileiro de Geografia e Estatística), 2004.
5.    Labib M. The investigation and management of obesity. J Clin Pathol 2003; 56: 17-25.
6.    Wolf AM, Colditz GA. Social and economic effects of body weight in the United States. Am J Clin Nutr 1996; 63: 466S-9S.
7.    Allison DB, Fontaine KR, Manson JE, Stevens J, VanItallie TB. Annual deaths attributable to obesity in the United States. JAMA 1999; 282:1530-8.
8.    World Health Organization (WHO). Obesity: preventing and managing the global epidemic. Tech Rep Series no 894. Geneva: WHO, 2000.
9.    The IDF consensus worldwide definition of metabolic syndrome. http://www.idf.org.
10.    Hans TS et al. Waist circumference action levels in identification of cardiovascular risk factors: prevalence study in a random sample. BMJ 1995; 311: 1401-5.
11.    AACE/ACE Obesity Task Force. AACE/ACE position statement on the prevention, diagnosis, and treatment of obesity (1998 Revision). Endocrine Practice 1998; 4: 297-349.
12.    Ravussin E, Swinburn BA. Pathophysiology of obesity. Lancet 1992; 340: 404-9.
13.    Willet WC. Is dietary fat a major determinant of body fat? Am J Clin Nutr 1988; 67 (suppl) 556S-62S.
14.    Saris WHM. Sugars, energy metabolism, and body weight control. Am J Clin Nutr 2003; 78 (suppl): 850S-7S.
15.    Costa AA, Neto JSA. Índice glicêmico. Em: Manual de Diabetes: educação, alimentação, medicamentos, atividades físicas. Brasil: Sarvier, 2004; 34-5.
16.    Acheson KJ. Carbohydrate and weight control: where do we stand? Curr Opin Nutr Metab Care 2004; 7: 485-92.
17.    Foster-Powell K, Holt SHA, Brand-Milller JC. International table of glycemic index and glycemic load values: 2002. Am J Clin Nutr 2002; 76: 5-56.
18.    Brand-Miller JC, Holt SHA, Pawlak DB, McMillan J. Glicemic index and obesity. Am J Clin Nutr 2002; 76 (suppl): 281S-5S.
19.    Ludwig DS. The glycemic index: physiological mechanisms relating to obesity, diabetes,and cardiovascular disease. JAMA 2002; 287: 2414-23.
20.    Pawlak DB, Ebbeling CB, Ludwig DS. Should obese patients be counselled to follow a low-glycaemic index diet? Yes. Obes Rev 2002; 3: 235-43.
21.    Lara-Castro C, Garvey WT. Diet, insulin resistence, and obesity: zoning in on data for Atkins dieters living in South Beach. JCEM 2004; 89: 4197-205.
22.    Ludwig DS. Glycemic load comes of age. J Nutr 2003; 133: 2695-6.
23.     Raben A. Should obese patients be counselled to follow a low-glycaemic index diet? No. Obes Rev 2002; 3: 245-56.
24.    Bray GA, Popkin BM. Dietary fat intake does affect obesity! Am J Clin Nutr 1998; 68: 1157-73.
25.    Tuomilehto J et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-50.
26.    Diabetes Prevention Program Research Group. Reduction in incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
27.    Samaha FF et al. A low-carbohydrate as compared with a low-fat diet in severe obesity. N Engl J Med 2003; 348: 2074-81.
28.    Foster GD et al. A randomized trial of low-carbohydrate diet for obesity. N Engl J Med 2003; 348: 2082-90.
29.    Brehm BJ, Seeley RJ, Daniels SR, D’Alessio DA. A randomized trial comparing a very low carbohydrate diet and a calorie-restricted low fat diet on body weight and cardiovascular risk factors in healthy women. J Clin Endocrinol Metab 2003; 88: 1617-23.
30.    Sondike SB, Copperman N, Jacobson MS. Effects of a low-carbohydrate diet on weight loss and cardiovascular risk factors in owerweight adolescents. J Pediatr 2003; 142: 253-8.
31.    Denke MA. Metabolic effects of high-protein, low-carbohydrate diets. Am J Cardiol 2001; 88: 59-61.
32.    Franz MJ. The answer to weight loss is easy – doing it is hard! Clinical Diabetes 2001; 19: 105-9.
33.    Noakes M, Clifton P. Weight loss, diet composition and cardiovascular risk. Curr Opin Lipidol 2004; 15: 31-5.
34.    van Dam RM, Willett WC, Rimm EB, Stampfer MJ, Hu FB. Dietary fat and meat intake in relation to risk of type 2 diabetes in men. Diabetes Care 2002; 25: 417-24.
35.    Hu FB, Willett WC. Optimal diets for prevention of coronary heart disease. JAMA 2002; 288: 2569-78.
36.    Bravata DM et al. Efficacy and safety of low-carbohydrate diets: a systematic review. JAMA 2003; 289: 1837-50.
37.    Teegarden D. The influence of dairy product consumption on body composition. J Nutr. 2005; 135: 2749-52.
38.    Zemel M. Calcium modulation of adiposity. Obes Res 2003; 11: 375-6.
39.    Lorenzen JK, Molgaard C, Michaelsen KF, Astrup A. Calcium supplementation for 1 y does not reduce body weight or fat mass in young girls. Am J Clin Nutr. 2006; 83: 18-23.
40.    Harvey-Berino J, Gold BC, Lauber R, Starinski A. The impact of calcium and dairy product consumption on weight loss. Obes Res. 2005; 13:1720-6.
41.    Heymsfield SB, van Mierlo CAJ, van der Knaap HCM, M Heo, Frier HI. Weight management using a meal replacement strategy: meta and pooling analysis from six studies. Int J Obes 2003; 27: 537-49.
42.    Flechtner-Mors M, Ditschuneit HH, Johnson TD, Suchard MA, Adler G. Metabolic and weight loss effects of long-term dietary intervention in obese patients: four-year results. Obes Res 2000; 8: 399-402.
43.    Ashley JM et al. Weight control in the physician’s office. Arch Int Med 2001; 151: 1599-1604.
44.    Ditschuneit HH, Flechtner-Mors M, Johnson TD, Adler G. Metabolic and weight-loss effects of a long-term dietary intervention in obese patients. Am J Clin Nutr 1999; 69: 198-204.
45.    Rothacker DQ. Five-year self-management of weight using meal replacements: comparison with matched controls in rural Wisconsin. Nutrition 2000; 16: 344-8.
46.    Wing RR, Jeffery RW. Food provision as a strategy to promote weight loss. Obes Res 2001; 9: 271S-5S.
47.    Kopelman PG. Practical prescribing. In: Medeiros-Neto G, Halpern A, Bouchard C. Progress in Obesity Research: 9. France: Editions John Libbey Eurotext; 2003. p. 881-6.
48.     Klein S, Romijn JA. Obesity. In: Larsen PR, Kronenberg HM, Melmed S, Polonsky KS. Williams Textbook of Endocrinology: Tenth Edition. USA: Saunders; 2003. p. 1619-41.
49.    Matos AFG, Carraro LM. Tratamento medicamentoso da obesidade. In: Vilar L et al. Endocrinologia Clínica: 2ª edição.Medsi; 2001. p. 747-63.
50.     Halpern A, Mancini MC. Diabesity: are weight loss medications effective? Treat Endocrinol 2005; 4: 65-74.
51.    Mayer LE, Walsh BT. The use of selective serotonin reuptake inhibitors in eating disorders. J Clin Psychiatry. 1998; 59 (Suppl 15):28-34.
52.    Connolly HM et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997:337: 581-8.
53.    Ioannides-Demos LL, Proietto J, McNeil JJ. Pharmacotherapy for obesity. Drugs 2005; 65:1391-1418.
54.    Anti-obesity drugs guidance on appropriate prescribing and management. A report of a working party of the Nutrition Committee of the Royal College of Physicians. http://www.rcplondon.ac.uk/news/news.asp?PR_id=171.
55.    Sjostrom LV. Mortality of severely obese subjects. Am J Clin Nutr 1992; 55: 516S-23S.
56.    Choban PS, Jackson B, Poplawski S, Bistolarides P. Bariatric surgery for morbid obesity: why, when, how, wher, and then what? Clev Clin J Med 2002; 69: 897-903.
57.    Expert Panel on Weight Loss Surgery – Executive Report, Ridley. Obes Res 2005; 13: 205-26.
58.    Freedman MR, King J, Kennedy E. Popular diets: a scientific review. Obes Res 2001; 9(suppl): 1S-40S.
59.    Phelan S, Wadden TA. Combining behavioral and pharmacological treatments for obesity. Obes Res 2002; 10: 560-74.
trans 
Get Adobe Flash player

IMeN - Instituto de Metabolismo e Nutrição
Rua Abílio Soares, 233 cj 53 • São Paulo • SP • Fone: (11) 3287-1800 • 3253-2966 • imen@nutricaoclinica.com.br